Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Nearly 25% of U.S. Adults Take an Obesogenic Prescription Drug
Key clinical point: Clinicians should try to minimize use of obesogenic drugs and focus on prescribing agents that are weight neutral or that trigger weight loss.
Major finding: During 2013-2016, 23% of U.S. adults had used at least one obesogenic prescription drug during the previous 30 days.
Study details: NHANES, a survey of a representative sample of U.S. residents during 2013-2016.
Disclosures: NHANES is run by the U.S. Centers for Disease Control and Prevention and receives no commercial funding. The authors reported no conflicts of interest.
Citation:
Hales CM et al. Obesity Week 2019, Abstract T-OR-2037.